Stockreport

Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia

MELINTA THERAPEUTICS INC  (MLNT) 
Last melinta therapeutics inc earnings: 11/12 04:39 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.melinta.com/investor-relations
PDF ~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia (CABP) ~ [Read more]